OTCM
RVVTF
Market cap10mUSD
Jul 09, Last price
0.02USD
1D
3.56%
1Q
-18.48%
Jan 2017
-71.99%
IPO
-95.57%
Name
Revive Therapeutics Ltd
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
31.47%
Rev. gr., 5y
%
Revenues
0k
Net income
-11m
L+95.98%
CFO
-768k
L-76.67%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Revive Therapeutics Ltd., a life sciences firm founded in 2012 and headquartered in Toronto, Canada, is focused on discovering and advancing treatments for uncommon diseases and infectious illnesses. The company maintains a pharmaceutical pipeline centered on cannabinoids, specifically targeting rare inflammatory conditions. Key developments in its therapeutic portfolio include: Bucillamine: Currently in Phase 3 clinical trials, it is being investigated for combating infectious diseases such as influenza and COVID-19. Psilocybin: This compound is in Phase 1 clinical studies for its potential in treating methamphetamine use disorder. Psilocin: The company is exploring its application for a range of mental health challenges, including depression, anxiety, bipolar disorder, bulimia, and anorexia nervosa. Cannabidiol (CBD): This is under investigation for its use in autoimmune hepatitis and for reducing ischemia and reperfusion injury that can occur after organ transplantation. Revive Therapeutics Ltd. also engages in several strategic research partnerships. These collaborations include an alliance with PharmaTher Inc. to develop psilocybin for cancer treatment and to identify new applications for other psychedelic compounds; a project with North Carolina State University to create a biosynthetic version of psilocybin through an enzymatic platform; a joint effort with the University of California, San Francisco, to assess Bucillamine's effectiveness against severe COVID-19; clinical research into psychedelics with the University of Health Sciences Antigua; and another collaboration with PharmaTher for the advancement of a psilocybin microneedle patch.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||